Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Merck Research VP Greene Has Advisory Committee Experience

Executive Summary

Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.

You may also be interested in...



Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July

Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.

Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July

Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.

Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth

U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel